These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. State of play and clinical prospects of antibody gene transfer. Hollevoet K; Declerck PJ J Transl Med; 2017 Jun; 15(1):131. PubMed ID: 28592330 [TBL] [Abstract][Full Text] [Related]
64. Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology. Naoum GE; Buchsbaum DJ; Tawadros F; Farooqi A; Arafat WO Oncol Rev; 2017 Mar; 11(1):332. PubMed ID: 28584572 [TBL] [Abstract][Full Text] [Related]
65. State of the art in tumor antigen and biomarker discovery. Even-Desrumeaux K; Baty D; Chames P Cancers (Basel); 2011 Jun; 3(2):2554-96. PubMed ID: 24212823 [TBL] [Abstract][Full Text] [Related]
66. Immunotherapeutic organoids: a new approach to cancer treatment. Compte M; Nuñez-Prado N; Sanz L; Alvarez-Vallina L Biomatter; 2013; 3(1):. PubMed ID: 23507921 [TBL] [Abstract][Full Text] [Related]
67. Gene therapy of malignant solid tumors by targeting erbB2 receptors and by activating T cells. Hu WX; Chen HP; Yu K; Shen LX; Wang CY; Su SZ; Sui WJ; Shan DM; Li HZ Cancer Biother Radiopharm; 2012 Dec; 27(10):711-8. PubMed ID: 22988969 [TBL] [Abstract][Full Text] [Related]
68. Effective Genetic Expression of Nanoantibodies by Recombinant Adenoviral Vector in vitro. Gribova IY; Tillib SV; Tutykhina IL; Shmarov CE; Logunov DY; Verkhovskaya LV; Naroditskii BS; Gintsburg AL Acta Naturae; 2011 Jul; 3(3):64-70. PubMed ID: 22649695 [TBL] [Abstract][Full Text] [Related]
69. Adenoviral vector-based strategies for cancer therapy. Sharma A; Tandon M; Bangari DS; Mittal SK Curr Drug ther; 2009 May; 4(2):117-138. PubMed ID: 20160875 [TBL] [Abstract][Full Text] [Related]
70. Targeting of adenoviral vectors through a bispecific single-chain antibody. Haisma HJ; Grill J; Curiel DT; Hoogeland S; van Beusechem VW; Pinedo HM; Gerritsen WR Cancer Gene Ther; 2000 Jun; 7(6):901-4. PubMed ID: 10880021 [TBL] [Abstract][Full Text] [Related]
71. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. Li X; Stuckert P; Bosch I; Marks JD; Marasco WA Cancer Gene Ther; 2001 Aug; 8(8):555-65. PubMed ID: 11571533 [TBL] [Abstract][Full Text] [Related]
72. Adenoviral-mediated delivery of gastrin-releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo. Rosenfeld ME; Rogers BE; Khazaeli MB; Mikheeva G; Raben D; Mayo MS; Curiel DT; Buchsbaum DJ Clin Cancer Res; 1997 Jul; 3(7):1187-94. PubMed ID: 9815798 [TBL] [Abstract][Full Text] [Related]
73. Targeted tumor killing via an intracellular antibody against erbB-2. Deshane J; Siegal GP; Alvarez RD; Wang MH; Feng M; Cabrera G; Liu T; Kay M; Curiel DT J Clin Invest; 1995 Dec; 96(6):2980-9. PubMed ID: 8675670 [TBL] [Abstract][Full Text] [Related]
74. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Arafat WO; Gómez-Navarro J; Buchsbaum DJ; Xiang J; Wang M; Casado E; Barker SD; Mahasreshti PJ; Haisma HJ; Barnes MN; Siegal GP; Alvarez RD; Hemminki A; Nettelbeck DM; Curiel DT Gene Ther; 2002 Feb; 9(4):256-62. PubMed ID: 11896464 [TBL] [Abstract][Full Text] [Related]